Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Micro-cold-forming: a simple, rapid, and inexpensive method for the fabrication of microcavities for 3D cell culture.

RSC advances·2026
Same author

Biomaterial Screening Identifies Enhanced Osteogenic and Angiogenic Potential of Mn-Doped Calcium Phosphate Coatings.

ACS biomaterials science & engineering·2026
Same author

pH-Responsive Nanoparticle-Coated Calcium Phosphate Granules for Bone Cancer Therapy.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Multifunctional Porous Microshuttles as Scaffolding Components and Carriers of Bioactive Factors in Self-Assembled Microtissues.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Real-Time Monitoring of the Formation and Culture of Hybrid Cell-Microbiomaterial Spheroids Using Non-Faradaic Electrical Impedance Spectroscopy.

ACS biomaterials science & engineering·2025
Same author

Hypoxic Preconditioning Enhances the Potential of Mesenchymal Stem Cells to Treat Neonatal Hypoxic-Ischemic Brain Injury.

Stroke·2025

Related Experiment Video

Updated: Aug 2, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K

Selenium-incorporated mesoporous silica nanoparticles for osteosarcoma therapy.

Lei He1, Pamela Habibovic1, Sabine van Rijt1

  • 1Department of Instructive Biomaterials Engineering, MERLN Institute for Technology Inspired Regenerative Medicine, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. s.vanrijt@maastrichtuniversity.nl.

Biomaterials Science
|April 19, 2023
PubMed
Summary

Mesoporous silica nanoparticles effectively deliver selenium compounds to inhibit osteosarcoma cells. These nanoparticles show selective toxicity, sparing healthy bone cells, and induce cancer cell death via reactive oxygen species.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K
Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies
03:11

Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies

Published on: June 7, 2024

737

Related Experiment Videos

Last Updated: Aug 2, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K
Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies
03:11

Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies

Published on: June 7, 2024

737

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Cancer Therapeutics

Background:

  • Selenium compounds show promise as chemotherapeutics by generating reactive oxygen species (ROS) to inhibit cancer cell activity.
  • Targeted intracellular delivery of selenium is crucial to minimize adverse effects on healthy bone cells.
  • Mesoporous silica nanoparticles (MSNs) offer biocompatibility, endocytosis-driven uptake, and tunable structures for efficient therapeutic ion delivery.

Purpose of the Study:

  • To develop and investigate MSNs for selective intracellular delivery of selenium (Se) to inhibit osteosarcoma (OS) cells.
  • To synthesize and characterize three distinct MSN formulations for Se delivery: surface-loaded (MSN-SeL), doped (Se-MSNs), and silica-coated nanoparticles (SeNP-MSNs).
  • To evaluate the efficacy and safety profile of these Se-loaded MSNs in targeting cancer cells while sparing healthy osteoblasts.

Main Methods:

  • Synthesis and characterization of three types of selenium-loaded MSNs (MSN-SeL, Se-MSNs, SeNP-MSNs).
  • Assessment of Se release profiles under physiological conditions, particularly in the presence of glutathione (GSH) and NADPH.
  • Evaluation of nanoparticle cytotoxicity towards SaoS-2 osteosarcoma cells and healthy osteoblasts.
  • Investigation of ROS generation and apoptosis induction in cancer cells treated with the synthesized nanoparticles.

Main Results:

  • All synthesized MSN formulations demonstrated stability in neutral conditions and rapid Se release in the presence of GSH and NADPH.
  • The nanoparticles exhibited significant cytotoxicity towards SaoS-2 cells, with notably lower toxicity towards healthy osteoblasts.
  • Se-doped MSNs (Se-MSNs) displayed the lowest toxicity towards osteoblasts among the tested formulations.
  • The MSNs successfully induced ROS production and promoted apoptosis in osteosarcoma cells.

Conclusions:

  • MSNs are effective carriers for intracellular selenium delivery, offering a promising strategy for osteosarcoma therapy.
  • The developed MSN formulations exhibit selective cytotoxicity, targeting cancer cells while minimizing harm to healthy bone cells.
  • The ability of MSNs to induce ROS and apoptosis underscores their potential as targeted chemotherapeutic agents for osteosarcoma.